Which statement describes the parvovirus treatment described as experimental and limited to early infection?

• A. Canine parvovirus monoclonal antibody
• B. Interferon therapy
• C. Broad-spectrum antibiotics
• D. Vaccination

Answer: (A)

Passive immunotherapy with a monoclonal antibody against canine parvovirus illustrates a targeted antiviral approach that would only be effective if given early, before extensive intestinal damage occurs. The antibody binds CPV particles and neutralizes them, helping to limit viral replication and lessen disease severity in the initial phase of infection. This is described as experimental because it’s not part of standard, proven therapy and its benefit hinges on early administration. By contrast, broad-spectrum antibiotics treat potential secondary bacterial infections rather than the virus itself; vaccination prevents infection but does not treat an active case; and interferon therapy has not established use as an early, virus-neutralizing treatment for CPV.